Literature DB >> 35412131

Virus Entry Inhibitors: Past, Present, and Future.

Shan Su1, Wei Xu1, Shibo Jiang2.   

Abstract

The approval of enfuvirtide marked a milestone for the development of virus entry inhibitor-based antiviral therapeutics. Since then, more peptide-, small-molecule-, and protein-based entry inhibitors have been identified and approved for viral diseases. Here we reviewed the development of virus entry inhibitors and the advantages and disadvantages of peptide-, small-molecule-, and protein-based entry inhibitors, herein summarizing the future trend of these antivirals. Virus entry inhibitors take effect outside the host cell, making them good candidates for development as pre- and post-exposure prophylaxis, microbicides, and therapeutics. This chapter, as well as this book, provides more information on the development and modification of peptide-, small-molecule-, and protein-based virus entry inhibitors.
© 2022. Springer Nature Singapore Pte Ltd.

Entities:  

Keywords:  Entry inhibitor; Peptide; Small molecule; Therapeutics; Virus

Mesh:

Substances:

Year:  2022        PMID: 35412131     DOI: 10.1007/978-981-16-8702-0_1

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  67 in total

1.  Exceptionally potent and broadly cross-reactive, bispecific multivalent HIV-1 inhibitors based on single human CD4 and antibody domains.

Authors:  Weizao Chen; Yang Feng; Ponraj Prabakaran; Tianlei Ying; Yanping Wang; Jianping Sun; Camila D S Macedo; Zhongyu Zhu; Yuxian He; Victoria R Polonis; Dimiter S Dimitrov
Journal:  J Virol       Date:  2013-11-06       Impact factor: 5.103

2.  Large-Scale Screening and Identification of Novel Ebola Virus and Marburg Virus Entry Inhibitors.

Authors:  Manu Anantpadma; Jennifer Kouznetsova; Hang Wang; Ruili Huang; Andrey Kolokoltsov; Rajarshi Guha; Aaron R Lindstrom; Olena Shtanko; Anton Simeonov; David J Maloney; Wendy Maury; Douglas J LaCount; Ajit Jadhav; Robert A Davey
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

3.  Core structure of gp41 from the HIV envelope glycoprotein.

Authors:  D C Chan; D Fass; J M Berger; P S Kim
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

4.  Preclinical Optimization of gp120 Entry Antagonists as anti-HIV-1 Agents with Improved Cytotoxicity and ADME Properties through Rational Design, Synthesis, and Antiviral Evaluation.

Authors:  Francesca Curreli; Shahad Ahmed; Sofia M Benedict Victor; Ildar R Iusupov; Dmitry S Belov; Pavel O Markov; Alexander V Kurkin; Andrea Altieri; Asim K Debnath
Journal:  J Med Chem       Date:  2020-02-17       Impact factor: 7.446

5.  Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development.

Authors:  M R Boyd; K R Gustafson; J B McMahon; R H Shoemaker; B R O'Keefe; T Mori; R J Gulakowski; L Wu; M I Rivera; C M Laurencot; M J Currens; J H Cardellina; R W Buckheit; P L Nara; L K Pannell; R C Sowder; L E Henderson
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

6.  Engineered single human CD4 domains as potent HIV-1 inhibitors and components of vaccine immunogens.

Authors:  Weizao Chen; Yang Feng; Rui Gong; Zhongyu Zhu; Yanping Wang; Qi Zhao; Dimiter S Dimitrov
Journal:  J Virol       Date:  2011-06-29       Impact factor: 5.103

7.  Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1.

Authors:  A K Debnath; L Radigan; S Jiang
Journal:  J Med Chem       Date:  1999-08-26       Impact factor: 7.446

8.  Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells.

Authors:  F Cocchi; A L DeVico; A Garzino-Demo; S K Arya; R C Gallo; P Lusso
Journal:  Science       Date:  1995-12-15       Impact factor: 47.728

9.  IgG Fc-binding motif-conjugated HIV-1 fusion inhibitor exhibits improved potency and in vivo half-life: Potential application in combination with broad neutralizing antibodies.

Authors:  Wenwen Bi; Wei Xu; Liang Cheng; Jing Xue; Qian Wang; Fei Yu; Shuai Xia; Qi Wang; Guangming Li; Chuan Qin; Lu Lu; Lishan Su; Shibo Jiang
Journal:  PLoS Pathog       Date:  2019-12-05       Impact factor: 6.823

10.  A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.

Authors:  David R Boulware; Matthew F Pullen; Ananta S Bangdiwala; Katelyn A Pastick; Sarah M Lofgren; Elizabeth C Okafor; Caleb P Skipper; Alanna A Nascene; Melanie R Nicol; Mahsa Abassi; Nicole W Engen; Matthew P Cheng; Derek LaBar; Sylvain A Lother; Lauren J MacKenzie; Glen Drobot; Nicole Marten; Ryan Zarychanski; Lauren E Kelly; Ilan S Schwartz; Emily G McDonald; Radha Rajasingham; Todd C Lee; Kathy H Hullsiek
Journal:  N Engl J Med       Date:  2020-06-03       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.